Free Webinar: Understanding Buprenorphine & Other Drug Testing For Your Patients.

Support your patients with Substance Use Disorders and their families by knowing how to decipher their drug test accurately. Webinar works best when using google chrome.

Date: July 18th

When: 12:00 pm

Can't commit to that time? Registration includes access to the webinar on-demand.

Presented By:

Andrew Walsh

With twenty plus years of Clinical, Forensic and Quality Control Laboratory experience, Andrew is Aspenti's Director of Scientific Advisory Solutions. Andrew is responsible for providing onsite training for providers, along with providing an understanding of drug testing results. Andrew acts as a conduit between the laboratory and client experience.

Learning Objectives:

Appropriate use of urine drug testing in patients with substance use disorders relies upon the provider’s ability to interpret the test results. In an interactive format, this session is designed to highlight common challenges in urine drug test interpretation. Presenters will review case studies representing frequently misunderstood areas of testing for patients who are prescribed Buprenorphine, Fentanyl Diversion, and the complexities surrounding Cannabinoid (THC) testing.

  • Review the role of urine drug testing in clinical cases that involve Buprenorphine, Fentanyl, and Cannabinoids (THC).
  • Become more versed in your patients testing to provide better care.

Who Should Attend: 

Substance Use & Mental Health Clinicians, License Drug & Alcohol Counselors, Nurse Practitioners, and Treatment Center Directors.

Register Now